Researchers have identified a protein interaction that may help senescent cells survive, offering a possible new direction for aging research and the development of more selective senolytic strategies. The findings were highlighted in a Mini Review published in Geromedicine and summarized by News Medical on September 1, 2026.
Why senescent cells matter in aging and disease
Senescent cells are cells that have stopped dividing but remain metabolically active. Over time, they can accumulate in the body and contribute to chronic inflammation and tissue dysfunction, making them an important target in the search for ways to preserve health during aging.
The review, led by researchers at Kyoto University, focuses on the interaction between phosphoglycerate mutase 1 (PGAM1) and checkpoint kinase 1 (Chk1). The authors say this interaction is increased in multiple models of cellular senescence and appears to support a heightened form of glucose metabolism in senescent cells.
A metabolic pattern described as a pseudo-Warburg effect
According to the review, the PGAM1-Chk1 interaction can stabilize the transcription factor HIF-2alpha. The authors link that effect to glycolysis, the pentose phosphate pathway and lactate production, as well as FoxM1-dependent DNA-repair and anti-apoptotic programs. Taken together, these pathways may help senescent cells remain viable under stress.
The review describes this metabolic pattern as a pseudo-Warburg effect, distinguishing it from the classic cancer-associated metabolic program seen in rapidly growing cells.
Early work on Nutlin 3b points to a selective senolytic approach
The article also discusses preclinical work on Nutlin 3b, one optical isomer of a compound originally developed to affect the p53-MDM2 pathway. In the work summarized, Nutlin 3b disrupted the PGAM1-Chk1 interaction without blocking p53-MDM2 binding, selectively removed senescent cells in experimental systems, and showed an acceptable safety profile in young mice.
In aged mouse models, the reported findings included improvement in several age-related dysfunctions and reduced lung fibrosis.
Clinical use remains unproven
The authors stress that the findings are preclinical. Cellular senescence differs across tissues and cell types, and the review notes that Nutlin 3b was active against senescent fibroblasts and macrophages in vitro, but not against senescent endothelial cells. Its feasibility in people remains unknown.
Before any clinical application, researchers will need to establish pharmacokinetics, long-term safety, dosing, tissue distribution and biomarkers for selecting and monitoring patients.
By bringing metabolic regulation, DNA repair and cell-survival signaling into a single framework, the authors argue that the PGAM1-Chk1 axis may help explain why certain senescent-cell populations persist. The proposed mechanism could guide future work on senolytics while underscoring the need for tissue-specific and safety-focused testing. More details are available in the source report from News Medical and the journal reference linked there. News Medical report Journal reference
Photo source: AI-generated or edited image
